tamoxifen / ACLY Cancer Research Results

Tam, tamoxifen: Click to Expand ⟱
Features:
Tamoxifen is an endocrine anti-hormone drug used to treat breast cancer and other tumours. Tamoxifen is a hormone therapy that treats or prevents hormone receptor-positive breast cancer.

Tamoxifen (TAM; brands include Nolvadex, Soltamox) — an oral selective estrogen receptor modulator (SERM) used primarily for ER+ breast cancer treatment and risk-reduction. Acts as an estrogen receptor antagonist in breast tissue, with partial agonist effects in other tissues.

Primary mechanisms (conceptual rank):
1) ER antagonism in breast → ↓ estrogen-driven transcription/proliferation
2) Prodrug activation to endoxifen (CYP2D6-dependent) → clinical response modulation
3) Cell-cycle arrest + apoptosis downstream of ER blockade (context-dependent)
4) Tumor microenvironment / growth factor cross-talk modulation (e.g., IGF signaling; context-dependent)

Bioavailability / PK relevance: Long half-life; highly protein-bound; hepatic metabolism. Conversion to active metabolite endoxifen depends in part on CYP2D6 activity and interacting drugs. :contentReference[oaicite:0]{index=0}

In-vitro vs oral exposure: Many non-ER “off-target” cytotoxic mechanisms (e.g., lysosomal/mitochondrial disruption) are reported at higher concentrations than typical clinical free-drug exposure; clinically dominant mechanism is ER modulation in ER+ disease. :contentReference[oaicite:1]{index=1}

Clinical evidence status: Established standard therapy and prevention option for ER+ breast cancer; labeling includes serious risks (uterine malignancies and thromboembolic events).

Tamoxifen — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Estrogen Receptor (ERα) transcriptional program ↓ (primary; ER+) ↔ / ↑ (tissue-dependent partial agonism) R/G Antiestrogen growth blockade Core mechanism in ER+ breast cancer; antagonist in breast, partial agonist in endometrium/bone context. :contentReference[oaicite:3]{index=3}
2 Endoxifen activation (CYP2D6-dependent) ↑ efficacy with adequate activation ↔ G Active metabolite exposure Tamoxifen is a prodrug; CYP2D6 affects endoxifen levels and may affect outcomes (drug interactions can matter). :contentReference[oaicite:4]{index=4}
3 Cell cycle (G1 checkpoint; cyclin/CDK) ↓ proliferation (ER+) ↔ G Cytostatic growth arrest Downstream of ER blockade; strongest in hormone-dependent contexts. :contentReference[oaicite:5]{index=5}
4 Apoptosis ↑ (context-dependent) ↔ G Tumor cell death in responsive settings Typically secondary to sustained estrogen deprivation/ER antagonism; variable by tumor biology. :contentReference[oaicite:6]{index=6}
5 PI3K/AKT/mTOR cross-talk ↔ / ↓ (context-dependent) ↔ R/G Growth-factor pathway interplay Common resistance axis in endocrine therapy; not tamoxifen’s primary biochemical target. :contentReference[oaicite:7]{index=7}
6 ROS ↔ / ↑ (high concentration only) ↔ P/R Not a dominant on-target axis Oxidative/mitochondrial effects are reported mainly in vitro at higher concentrations than typical free systemic exposure.
7 NRF2 ↔ ↔ R/G No primary modulation Not a canonical tamoxifen mechanism.
8 HIF-1α ↔ ↔ G No primary role Any hypoxia-axis effects are indirect and model-dependent.
9 Ferroptosis ↔ (not established) ↔ R/G Not canonical Not an established primary mechanism for tamoxifen.
10 Ca²⁺ signaling ↔ ↔ P/R No primary role Not a dominant on-target axis.
11 Clinical Translation Constraint ↓ (constraint) ↓ (toxicity) — Risk + interactions + resistance Key constraints include uterine malignancy and thromboembolic risks (esp. prevention setting), CYP2D6-dependent activation/interaction issues, and endocrine resistance. :contentReference[oaicite:8]{index=8}

TSF legend: P: 0–30 min (receptor binding); R: 30 min–3 hr (acute transcriptional signaling shifts); G: >3 hr (cell-cycle/apoptosis phenotypes)
ACLY, ATP citrate lyase: Click to Expand ⟱
Source:
Type:
ACLY links energy metabolism provided by catabolic pathways to biosynthesis. ACLY, which has been found to be overexpressed in many cancers, converts citrate into acetyl-CoA and OAA.ATP citrate lyase exhibited upregulation in various tumours.
General Tumour Biomarker
•ACLY is a key enzyme in cancer metabolism.
•ACLY is involved in glucose and lipid metabolism.
•Many ACLY inhibitors were developed as anti-cancer agents.

ACLY is a key enzyme in cellular metabolism that converts citrate into acetyl‐CoA and oxaloacetate. Acetyl‐CoA is a substrate for lipid synthesis and protein acetylation, processes that are often upregulated in cancer cells to support rapid growth and proliferation.

ACLY is found overexpressed in many aggressive cancers. ACLY abundantly consumes citrate from nutrient catabolism (especially glucose and glutamine) to support protein acetylation and intense nucleotide and lipid synthesis. The significant decrease in cytosolic citrate appears to play a central role in cancer metabolism by enhancing the Warburg effect and activating the PI3K / AKT axis promoting ACLY activity in a feedback loop. Thus, the inhibition of factors regulating its expression (such as SREBP1) and its activation (such as AKT) could have an anti-proliferative effect.

Elevated ACLY expression has been observed in a number of cancers. In many studies, high levels of ACLY have been associated with more aggressive disease and poorer prognoses.

Natural ACLY Inhibitors
-Hydroxycitrate (HCA):(widely studied)
-EGCG
-Quercetin
-Resveratrol
-Luteolin
-Citrate
-Cucurbitacin B
-Emodin?
Scientific Papers found: Click to Expand⟱
293- HCA,  Tam,    Hydroxycitric acid potentiates the cytotoxic effect of tamoxifen in MCF-7 breast cancer cells through inhibition of ATP citrate lyase
- in-vitro, BC, MCF-7
TumCG↓, Apoptosis↑, ACLY↓, ACC-α↓, Fas↓,
1629- HCA,  Tam,    Hydroxycitric acid reverses tamoxifen resistance through inhibition of ATP citrate lyase
- in-vitro, BC, MCF-7
ACLY↓, eff↓, tumCV↓, eff↑, Casp3↑, BAX↑, Bcl-2↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

ACC-α↓, 1,   ACLY↓, 2,  

Cell Death ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Fas↓, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↓, 1,   eff↑, 1,  
Total Targets: 11

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: ACLY, ATP citrate lyase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:189  Target#:2  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page